LNK 01009
Alternative Names: LNK-01009Latest Information Update: 31 Mar 2025
At a glance
- Originator Lynk Pharmaceuticals
- Class Anti-inflammatories
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases; Metabolic disorders; Systemic lupus erythematosus
Most Recent Events
- 18 Feb 2025 Preclinical trials in Inflammatory bowel diseases in USA (unspecified route) (Lynk Pharmaceuticals pipeline, February 2025)
- 18 Feb 2025 Preclinical trials in Metabolic disorders in USA (unspecified route) (Lynk Pharmaceuticals pipeline, February 2025)
- 18 Feb 2025 Preclinical trials in Systemic lupus erythematosus in USA (unspecified route) (Lynk Pharmaceuticals pipeline, February 2025)